Tim Opler, Flame Biosciences co-CEO
January 11, 2023 12:48 PM ESTUpdated 05:25 PM
Startups
R&D

Flame Bio­sciences search­es for fu­ture af­ter No­var­tis flunks on canakinum­ab

Kyle LaHucik

Senior Reporter

Flame Bio­sciences de­buted with the idea that its mon­o­clon­al an­ti­body that in­hibits IL-1ß, a key cy­tokine in in­flam­ma­tion, would be ef­fec­tive at re­duc­ing can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times